TG Therapeutics Inc
NASDAQ:TGTX

Watchlist Manager
TG Therapeutics Inc Logo
TG Therapeutics Inc
NASDAQ:TGTX
Watchlist
Price: 35.07 USD 1.51% Market Closed
Market Cap: 5.5B USD
Have any thoughts about
TG Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one TGTX stock under the Base Case scenario is 23.8 USD. Compared to the current market price of 35.07 USD, TG Therapeutics Inc is Overvalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TGTX Intrinsic Value
23.8 USD
Overvaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
TG Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TGTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TGTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
TG Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about TG Therapeutics Inc

Provide an overview of the primary business activities
of TG Therapeutics Inc.

What unique competitive advantages
does TG Therapeutics Inc hold over its rivals?

What risks and challenges
does TG Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in TG Therapeutics Inc recently?

Summarize the latest earnings call
of TG Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for TG Therapeutics Inc.

Provide P/S
for TG Therapeutics Inc.

Provide P/E
for TG Therapeutics Inc.

Provide P/OCF
for TG Therapeutics Inc.

Provide P/FCFE
for TG Therapeutics Inc.

Provide P/B
for TG Therapeutics Inc.

Provide EV/S
for TG Therapeutics Inc.

Provide EV/GP
for TG Therapeutics Inc.

Provide EV/EBITDA
for TG Therapeutics Inc.

Provide EV/EBIT
for TG Therapeutics Inc.

Provide EV/OCF
for TG Therapeutics Inc.

Provide EV/FCFF
for TG Therapeutics Inc.

Provide EV/IC
for TG Therapeutics Inc.

Show me price targets
for TG Therapeutics Inc made by professional analysts.

What are the Revenue projections
for TG Therapeutics Inc?

How accurate were the past Revenue estimates
for TG Therapeutics Inc?

What are the Net Income projections
for TG Therapeutics Inc?

How accurate were the past Net Income estimates
for TG Therapeutics Inc?

What are the EPS projections
for TG Therapeutics Inc?

How accurate were the past EPS estimates
for TG Therapeutics Inc?

What are the EBIT projections
for TG Therapeutics Inc?

How accurate were the past EBIT estimates
for TG Therapeutics Inc?

Compare the revenue forecasts
for TG Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of TG Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of TG Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of TG Therapeutics Inc compared to its peers.

Compare the P/E ratios
of TG Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing TG Therapeutics Inc with its peers.

Analyze the financial leverage
of TG Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for TG Therapeutics Inc.

Provide ROE
for TG Therapeutics Inc.

Provide ROA
for TG Therapeutics Inc.

Provide ROIC
for TG Therapeutics Inc.

Provide ROCE
for TG Therapeutics Inc.

Provide Gross Margin
for TG Therapeutics Inc.

Provide Operating Margin
for TG Therapeutics Inc.

Provide Net Margin
for TG Therapeutics Inc.

Provide FCF Margin
for TG Therapeutics Inc.

Show all solvency ratios
for TG Therapeutics Inc.

Provide D/E Ratio
for TG Therapeutics Inc.

Provide D/A Ratio
for TG Therapeutics Inc.

Provide Interest Coverage Ratio
for TG Therapeutics Inc.

Provide Altman Z-Score Ratio
for TG Therapeutics Inc.

Provide Quick Ratio
for TG Therapeutics Inc.

Provide Current Ratio
for TG Therapeutics Inc.

Provide Cash Ratio
for TG Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for TG Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for TG Therapeutics Inc?

What is the current Free Cash Flow
of TG Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for TG Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
TG Therapeutics Inc

Current Assets 389.2m
Cash & Short-Term Investments 217.3m
Receivables 83.6m
Other Current Assets 88.3m
Non-Current Assets 12.1m
Long-Term Investments 947k
PP&E 7.7m
Other Non-Current Assets 3.4m
Current Liabilities 108.7m
Accounts Payable 93.5m
Accrued Liabilities 7.7m
Other Current Liabilities 7.5m
Non-Current Liabilities 115m
Long-Term Debt 102.5m
Other Non-Current Liabilities 12.4m
Efficiency

Earnings Waterfall
TG Therapeutics Inc

Revenue
264.8m USD
Cost of Revenue
-30.9m USD
Gross Profit
233.9m USD
Operating Expenses
-234.4m USD
Operating Income
-505k USD
Other Expenses
-13.9m USD
Net Income
-14.4m USD

Free Cash Flow Analysis
TG Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the latest earnings call, TG Therapeutics reported third-quarter net sales of BRIUMVI at $83.3 million, marking a substantial 230% increase year-over-year. The company raised its full-year revenue guidance to $300-305 million, up from an earlier estimate of $220-260 million. BRIUMVI's profile remains strong, supported by favorable clinical data and growing market presence with nearly 1,100 prescribers targeting a 15% to 20% sequential sales growth in 2025. Additionally, the company plans to invest significantly in expanding commercial outreach and reducing infusion times, potentially positioning BRIUMVI as a leading therapy in the MS market.

What is Earnings Call?
Fundamental Scores

TGTX Profitability Score
Profitability Due Diligence

TG Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
36/100
Profitability
Score

TG Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

TGTX Solvency Score
Solvency Due Diligence

TG Therapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Low D/E
62/100
Solvency
Score

TG Therapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TGTX Price Targets Summary
TG Therapeutics Inc

Wall Street analysts forecast TGTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TGTX is 38.89 USD with a low forecast of 9.09 USD and a high forecast of 57.75 USD.

Lowest
Price Target
9.09 USD
74% Downside
Average
Price Target
38.89 USD
11% Upside
Highest
Price Target
57.75 USD
65% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TGTX?

Click here to dive deeper.

Dividends

TG Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TGTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TGTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

TGTX News

Other Videos

Profile

TG Therapeutics Inc Logo
TG Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

5.4B USD

Dividend Yield

0%

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 286 full-time employees. Its pipeline candidates include TG-1501 (Cosibelimab), TG-1701 (BTK inhibitor), TG-1801 (anti-CD47/anti-CD19 bispecific monoclonal antibody). Its UKONIQ (umbralisib) is developed for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed or refractory follicular lymphoma. The company has three programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis and patients with chronic lymphocytic leukemia and several investigational medicines in Phase I clinical development. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Contact

NEW YORK
New York City
2 Gansevoort St Fl 9
+12125544484.0
www.tgtherapeutics.com

IPO

1995-12-14

Employees

286

Officers

Chairman, CEO & President
Mr. Michael S. Weiss Esq.
CFO, Corporate Secretary & Treasurer
Mr. Sean A. Power CPA
Senior Vice President of Corporate Communications
Jenna Bosco
Chief Commercialization Officer
Mr. Adam Waldman

See Also

Discover More
What is the Intrinsic Value of one TGTX stock?

The intrinsic value of one TGTX stock under the Base Case scenario is 23.8 USD.

Is TGTX stock undervalued or overvalued?

Compared to the current market price of 35.07 USD, TG Therapeutics Inc is Overvalued by 32%.

Back to Top